Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Tanabe Pharma (MTZPY)

Tanabe Pharma (MTZPY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 17.85
  • Price/Book 1.32
Trade MTZPY with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.0000 +3.33%
on 05/06/20
18.6500 -0.27%
on 05/15/20
+0.2200 (+1.20%)
since 04/15/20
3-Month
15.2600 +21.89%
on 03/24/20
18.6500 -0.27%
on 05/15/20
+0.3900 (+2.14%)
since 02/14/20
52-Week
10.5900 +75.64%
on 08/29/19
18.8000 -1.06%
on 02/04/20
+7.0200 (+60.62%)
since 05/15/19

Most Recent Stories

More News
Mitsubishi Tanabe Pharma America Celebrates Fourth Anniversary of U.S. Availability of RADICAVA® (edaravone) for Treatment of ALS

/PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that nearly 6,000 people with amyotrophic lateral sclerosis (ALS) in the U.S. have received treatment with RADICAVA (edaravone)...

MTZPY : 18.6000 (-0.13%)
Global Pediatric Vaccine Market Research Report 2021: Market is Expected to Reach $49.9 Billion in 2025 - Long-term Forecast to 2030

/PRNewswire/ -- The report has been added to offering.

AZN : 55.56 (-1.84%)
CSLLY : 112.3400 (-0.17%)
GSK : 38.93 (-0.46%)
MRK : 71.68 (-0.40%)
MTZPY : 18.6000 (-0.13%)
PFE : 43.89 (-1.30%)
Mitsubishi Tanabe Pharma America and Target ALS Announce Call for Nominations for First Annual Rebecca Luker Courage Award

/PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Target ALS today announced the establishment of the inaugural Target ALS Rebecca Luker Courage Award. The award will spotlight individuals...

MTZPY : 18.6000 (-0.13%)
Diabetic Nephropathy Market Report 2021-2028 | Size, Share, Growth, Trends, Competitive Landscape, Revenue, Analysis, Forecast Report

The increasing prevalence of diabetes around the world is expected to spur opportunities for the market during the forecast period, states Fortune Business Insights in a report, titled "Diabetic Nephropathy...

BAYRY : 13.2900 (-1.41%)
GE : 100.47 (-0.86%)
MTZPY : 18.6000 (-0.13%)
NVS : 83.48 (-1.07%)
SIEGY : 87.6600 (-0.93%)
PANTHERx® Rare Selected by Mitsubishi Tanabe Pharma America, Inc. (MTPA) as Exclusive Provider of U.S. Specialty Pharmacy Services for EXSERVAN™ (riluzole) oral film

July 8, 2021 /PRNewswire/ -- PANTHERx Rare announced today that it was selected by Mitsubishi Tanabe Pharma America, Inc. (MTPA) as the exclusive U.S. pharmacy distribution partner for EXSERVAN™ (riluzole)....

MTZPY : 18.6000 (-0.13%)
Mitsubishi Tanabe Pharma America Announces EXSERVAN™ (riluzole) is Now Available in the U.S. for the Treatment of ALS

/PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that EXSERVAN (riluzole), the first oral film formulation of riluzole, is now available in the U.S. for the treatment of...

MTZPY : 18.6000 (-0.13%)
Myasthenia Gravis Treatment Market Size, Share, Trends, Analysis and Forecast 2027

The report on Myasthenia Gravis Treatment provides the clients with a comprehensive analysis of crucial driving factors, consumer behavior, growth trends, product utilization, key player analysis, brand...

ARGX : 331.67 (+2.50%)
ALPMF : 17.2500 (+0.88%)
AVDL : 7.95 (-0.38%)
BAX : 83.61 (+0.47%)
GSK : 38.93 (-0.46%)
GRFS : 15.39 (+6.51%)
MTZPY : 18.6000 (-0.13%)
NVS : 83.48 (-1.07%)
RARX : 48.00 (-0.03%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
MTPA Announces PANTHERx® Selected as Exclusive Provider of U.S. Specialty Pharmacy Services for EXSERVAN™ (riluzole) Oral Film

/PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced PANTHERx Rare Pharmacy has been selected as the exclusive provider of specialty pharmacy services for EXSERVAN (riluzole),...

MTZPY : 18.6000 (-0.13%)
Mitsubishi Tanabe Pharma America to Present Analysis of Real-World Claims Data for Patients Treated With RADICAVA® (edaravone) During 2021 European Network to Cure ALS (ENCALS) Virtual Meeting

, /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced it will present findings from a new analysis of claims data from a cohort of patients who received RADICAVA (edaravone)...

MTZPY : 18.6000 (-0.13%)
Global Vaccines Market Analysis Report 2021: Forecast to 2025 Featuring Sinopharm, Serum Institute, Novavax, Moderna, Mitsubishi Tanabe Pharma, Emergent BioSolutions, and CSL

The "Vaccines Market - Global Industry Analysis (2017 - 2020), Growth Trends and Market Forecast (2021 - 2025)" report has been added to ResearchAndMarkets.com's offering.

MTZPY : 18.6000 (-0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 18.6733
1st Resistance Point 18.6367
Last Price 18.6000
1st Support Level 18.5767
2nd Support Level 18.5533
3rd Support Level N/A

See More

52-Week High 18.8000
Last Price 18.6000
Fibonacci 61.8% 15.6638
Fibonacci 50% 14.6950
Fibonacci 38.2% 13.7262
52-Week Low 10.5900

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar